As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases?
In the brief, the authors discuss how the failure of ICER’s analysis to evaluate the included therapies in the context of the broader context of RA treatment serves as an illustration of the limitations of conventional methods for value assessment. Modern value assessment methods, such as IVI’s RA model, may provide more relevant insights by comparing the full range of available therapies and varying treatment sequences to provide relevant insights to decision makers.
Read the press release and full brief here.
